Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by CreativeOne Wealth LLC

CreativeOne Wealth LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 190.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 8,408 shares of the company’s stock after purchasing an additional 5,514 shares during the period. CreativeOne Wealth LLC’s holdings in Neurocrine Biosciences were worth $969,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $30,000. EdgeRock Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd raised its position in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.1 %

Shares of NASDAQ NBIX opened at $126.75 on Friday. The stock has a fifty day moving average price of $119.26 and a 200 day moving average price of $131.61. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market cap of $12.83 billion, a P/E ratio of 33.98 and a beta of 0.35.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NBIX shares. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Guggenheim boosted their target price on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Jefferies Financial Group boosted their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Finally, Royal Bank of Canada decreased their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.